PuSH - Publication Server of Helmholtz Zentrum München

210 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Clemmensen, C. et al.: Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat. Rev. Endocrinol. 15, 90-104 (2019)
2.
Décarie-Spain, L.* et al.: GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. Neuropharmacol. 151, 55-63 (2019)
3.
Jall, S. et al.: Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice. Mol. Metab. 23, 75-81 (2019)
4.
Khajavi, N.* et al.: Tri-agonist-induced PLC activation is associated with robust insulin secretion from murine islets. Naunyn-Schmiedebergs Arch. Pharmakol. 392, S35-S35 (2019)
5.
Mroz, P.A.* et al.: Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol. Metab. 20, 51-62 (2019)
6.
Müller, G. ; Herling, A.W.* ; Stemmer, K. ; Lechner, A. & Tschöp, M.H.: Chip-based sensing of membrane release of unprocessed cell surface proteins in vitro and in serum and its (patho)physiological relevance. Am. J. Physiol. Endocrinol. Metab., accepted (2019)
7.
Müller, T.D. & Tschöp, M.H.: Glukagon, das vergessene Hormon. Diabetologe 15, 177-184 (2019)
8.
Niu, L.* et al.: Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol. Syst. Biol. 15:e8793 (2019)
9.
Quarta, C. et al.: Functional identity of hypothalamic melanocortin neurons depends on Tbx3. Nat. Metab. 1, 222-235 (2019)
10.
Ratner, C.* et al.: Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway. Diabetes 68, 1329-1340 (2019)
11.
Tschöp, M.H.: Toward neuroendocrine precision medicines for metabolic diseases. Chem. Senses 44, E1-E1 (2019)
12.
von Gamm, M. et al.: Immune homeostasis and regulation of the interferon pathway require myeloid-derived Regnase-3. J. Exp. Med., accepted (2019)
13.
Al-Massadi, O.* ; Müller, T.D. ; Tschöp, M.H. ; Diéguez, C.* & Nogueiras, R.*: Ghrelin and LEAP-2: Rivals in energy metabolism. Trends Pharmacol. Sci. 39, 685-694 (2018)
14.
Brandt, S. ; Götz, A. ; Tschöp, M.H. & Müller, T.D.: Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides 100, 190-201 (2018)
15.
Brandt, S. ; Kleinert, M. ; Tschöp, M.H. & Müller, T.D.: Are peptide conjugates the golden therapy against obesity? J. Endocrinol. 238, R109-R119 (2018)
16.
Brandt, S. ; Müller, T.D. ; DiMarchi, R.D.* ; Tschöp, M.H. & Stemmer, K.: Peptide-based multi-agonists: A new paradigm in metabolic pharmacology. J. Intern. Med. 284, 581-602 (2018)
17.
Capozzi, M.E.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Finan, B.* & Campbell, J.E.*: Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr. Rev. 39, 719-738 (2018)
18.
Cheng, Y. et al.: Prediction of adipose browning capacity by systematic integration of transcriptional profiles. Cell Rep. 23, 3112-3125 (2018)
19.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. Nat. Commun. 9:4304 (2018)
20.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes (vol 9, 4304, 2018). Nat. Commun. 9:4975 (2018)